ArticleThe Journal of clinical endocrinology and metabolism2020
A Role for Oncostatin M in the Impairment of Glucose Homeostasis in Obesity.
Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Suboptimal Selenium Intake Produces Sex-Specific Alterations in Metabolic Profiles in Western Diet-Fed Obese Mice.International journal of molecular sciences · 2026Article
- Interleukin-6 and Oncostatin M Levels in Patients With Type 1 Diabetes and Its Relationship With Glycemic Indices.Endocrinology, diabetes & metabolism · 2026Article
- Heterogeneity in clinically diagnosed type 1 diabetes: characterising a unique cohort with maintained C-peptide secretion in Ghana.Diabetologia · 2026Article
- Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation.Diabetology & metabolic syndrome · 2025Article
- DNA methylation-predicted protein differences between Yakutian and Central Russian populations.Epigenomics · 2025Article
- A Mendelian Randomization Study and Experimental Validation Investigating the Potential Relationship Among Interleukin-6 Receptor Subunit Beta, Obesity, and Alzheimer's Disease.Brain and behavior · 2025Article
- Multiomics reveal key inflammatory drivers of severe obesity: IL4R, LILRA5, and OSM.Cell genomics · 2025Article
- A machine learning approach to leveraging electronic health records for enhanced omics analysis.Nature machine intelligence · 2025Article
- Suppression of gp130 attenuated insulin-mediated signaling and glucose uptake in skeletal muscle cells.Scientific reports · 2024Article
- Article
- Metabolic and inflammatory perturbation of diabetes associated gut dysbiosis in people living with and without HIV infection.Genome medicine · 2024Article
- Exercise-induced crosstalk between immune cells and adipocytes in humans: Role of oncostatin-M.Cell reports. Medicine · 2024Article
- Oncostatin M's Involvement in the Pathogenesis of Chronic Rhinosinusitis: Focus on Type 1 and 2 Inflammation.Biomedicines · 2023Article
- Article
- Article
- Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis.BMC cardiovascular disorders · 2021Article
- The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans.International journal of obesity (2005) · 2021Article
- Adipocyte Oncostatin Receptor Regulates Adipose Tissue Homeostasis and Inflammation.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 2 countries.
Funding
Abstract
contextOncostatin M (OSM) plays a key role in inflammation, but its regulation and function during obesity is not fully understood.
objectiveThe aim of this study was to evaluate the relationship of OSM with the inflammatory state that leads to impaired glucose homeostasis in obesity. We also assessed whether OSM immunoneutralization could revert metabolic disturbances caused by a high-fat diet (HFD) in mice.
design28 patients with severe obesity were included and stratified into two groups: (1) glucose levels <100 mg/dL and (2) glucose levels >100 mg/dL. White adipose tissue was obtained to examine OSM gene expression. Human adipocytes were used to evaluate the effect of OSM in the inflammatory response, and HFD-fed C57BL/6J mice were injected with anti-OSM antibody to evaluate its effects.
resultsOSM expression was elevated in subcutaneous and visceral fat from patients with obesity and hyperglycemia, and correlated with Glut4 mRNA levels, serum insulin, homeostatic model assessment of insulin resistance, and inflammatory markers. OSM inhibited adipogenesis and induced inflammation in human adipocytes. Finally, OSM receptor knockout mice had increased Glut4 mRNA levels in adipose tissue, and OSM immunoneutralization resulted in a reduction of glucose levels and Ccl2 expression in adipose tissue from HFD-fed mice.
conclusionsOSM contributes to the inflammatory state during obesity and may be involved in the development of insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.